These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28838265)

  • 1. Ninety-day post-operative morbidity and mortality using the National Cancer Institute's common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Alyami M; Kim BJ; Villeneuve L; Vaudoyer D; Képénékian V; Bakrin N; Gilly FN; Cotte E; Glehen O; Passot G
    Int J Hyperthermia; 2018 Aug; 34(5):532-537. PubMed ID: 28838265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Where Oncologic and Surgical Complication Scoring Systems Collide: Time for a New Consensus for CRS/HIPEC.
    Lehmann K; Eshmuminov D; Slankamenac K; Kranzbühler B; Clavien PA; Vonlanthen R; Gertsch P
    World J Surg; 2016 May; 40(5):1075-81. PubMed ID: 26669784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes.
    Robella M; Vaira M; Cinquegrana A; De Simone M
    Minerva Chir; 2019 Jun; 74(3):195-202. PubMed ID: 29589675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Tan JW; Tan GHC; Ng WY; Ong CJ; Chia CS; Soo KC; Teo MCC
    Int J Clin Oncol; 2020 May; 25(5):984-994. PubMed ID: 31915944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morbidity of the abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
    Nunez MF; Sardi A; Nieroda C; Jimenez W; Sittig M; MacDonald R; Aydin N; Milovanov V; Gushchin V
    Ann Surg Oncol; 2015 May; 22(5):1658-63. PubMed ID: 25245127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does having a gastrectomy delay time to feeding and prolong hospital stay in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
    Shannon NB; Tan GHC; Chia CS; Soo KC; Teo MC
    Int J Hyperthermia; 2018 Aug; 34(5):518-523. PubMed ID: 28689443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy.
    Cascales Campos P; Martinez Insfran LA; Wallace D; Gil J; Gil E; Gonzalez Gil A; Martínez J; Alonso Romero JL; Gonzalez Sanchez R; Parrilla P
    Clin Transl Oncol; 2020 Jun; 22(6):852-859. PubMed ID: 31392644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy used as treatment of colo-rectal carcinomatosis: a multicentric study.
    Macrì A; Arcoraci V; Belgrano V; Caldana M; Carbonari L; Cioppa T; De Cian F; De Manzoni G; De Simone M; Giardina C; Muffatti F; Orsenigo E; Robella M; Roviello F; Saladino E; Sammartino P; Vaira M
    Updates Surg; 2020 Mar; 72(1):163-170. PubMed ID: 31729630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.
    Foster JM; Sleightholm R; Patel A; Shostrom V; Hall B; Neilsen B; Bartlett D; Smith L
    JAMA Netw Open; 2019 Jan; 2(1):e186847. PubMed ID: 30646202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open versus Closed technique for administration of heated intraperitoneal chemotherapy (HIPEC): Morbidity and Mortality outcomes from a high-volume centre.
    Hassan S; Dritsas S; O'Dwyer ST; Aziz O; Sutton P; Wang X; Fish R;
    Eur J Surg Oncol; 2023 Sep; 49(9):106924. PubMed ID: 37179147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-admissions for delayed complications after cytoreductive surgery and HIPEC.
    Spiliotis J; Argiriou EO; Vafias E; Manou V; Vaos N; Datsis A; Efstathiou E
    Acta Chir Belg; 2016 Apr; 116(2):96-100. PubMed ID: 27385296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
    Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis.
    Paredes AZ; Guzman-Pruneda FA; Abdel-Misih S; Hays J; Dillhoff ME; Pawlik TM; Cloyd JM
    J Surg Res; 2019 Sep; 241():31-39. PubMed ID: 31004870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure to rescue following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Li KY; Mokdad AA; Minter RM; Mansour JC; Choti MA; Augustine MM; Polanco PM
    J Surg Res; 2017 Jun; 214():209-215. PubMed ID: 28624046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
    Sin EI; Chia CS; Tan GHC; Soo KC; Teo MC
    Int J Hyperthermia; 2017 Sep; 33(6):690-695. PubMed ID: 28540777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
    Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.